BOLT BIOTHERAP. DL-00001(6LP)

Description: Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

---

Keywords: Cancer Biopharmaceutical Treatment Of Cancer Tumor Breast Cancer Cancer Immunotherapy Immunotherapies Genmab Positive Solid Tumors

---

Home Page: www.boltbio.com

900 Chesapeake Drive
Redwood City, CA 94063
United States
Phone: 650 665 9295

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)